T. Rowe Price Associates’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $402M | Sell |
|
|||||
|
2025
Q2 | $388M | Buy |
|
|||||
|
2025
Q1 | $170M | Buy |
|
|||||
|
2024
Q4 | $203M | Sell |
|
|||||
|
2024
Q3 | $193M | Sell |
|
|||||
|
2024
Q2 | $248M | Sell |
|
|||||
|
2024
Q1 | $251M | Buy |
|
|||||
|
2023
Q4 | $195M | Buy |
|
|||||
|
2023
Q3 | $133M | Sell |
|
|||||
|
2023
Q2 | $125M | Sell |
|
|||||
|
2023
Q1 | $141M | Sell |
|
|||||
|
2022
Q4 | $170M | Sell |
|
|||||
|
2022
Q3 | $155M | Sell |
|
|||||
|
2022
Q2 | $386M | Sell |
|
|||||
|
2022
Q1 | $402M | Sell |
|
|||||
|
2021
Q4 | $371M | Sell |
|
|||||
|
2021
Q3 | $428M | Sell |
|
|||||
|
2021
Q2 | $489M | Sell |
|
|||||
|
2021
Q1 | $561M | Sell |
|
|||||
|
2020
Q4 | $601M | Sell |
|
|||||
|
2020
Q3 | $618M | Sell |
|
|||||
|
2020
Q2 | $815M | Buy |
|
|||||
|
2020
Q1 | $569M | Sell |
|
|||||
|
2019
Q4 | $784M | Buy |
|
|||||
|
2019
Q3 | $606M | Buy |
|
|||||
|
2019
Q2 | $286M | Sell |
|
|||||
|
2019
Q1 | $306M | Sell |
|
|||||
|
2018
Q4 | $286M | Sell |
|
|||||
|
2018
Q3 | $724M | Sell |
|
|||||
|
2018
Q2 | $583M | Sell |
|
|||||
|
2018
Q1 | $520M | Buy |
|
|||||
|
2017
Q4 | $483M | Sell |
|
|||||
|
2017
Q3 | $442M | Buy |
|
|||||
|
2017
Q2 | $330M | Buy |
|
|||||
|
2017
Q1 | $178M | Sell |
|
|||||
|
2016
Q4 | $231M | Sell |
|
|||||
|
2016
Q3 | $474M | Buy |
|
|||||
|
2016
Q2 | $418M | Sell |
|
|||||
|
2016
Q1 | $379M | Sell |
|
|||||
|
2015
Q4 | $545M | Buy |
|
|||||
|
2015
Q3 | $349M | Sell |
|
|||||
|
2015
Q2 | $468M | Sell |
|
|||||
|
2015
Q1 | $392M | Sell |
|
|||||
|
2014
Q4 | $225M | Buy |
|
|||||
|
2014
Q3 | $156M | Sell |
|
|||||
|
2014
Q2 | $152M | Sell |
|
|||||
|
2014
Q1 | $165M | Buy |
|
|||||
|
2013
Q4 | $87M | Sell |
|
|||||
|
2013
Q3 | $113M | Buy |
|
|||||
|
2013
Q2 | $105M | Buy |
|